Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
NEW YORK, May 11, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased TherapeuticsMD, Inc. ("TherapeuticsMD") (NYSEMKT:TXMD) securities between July 7, 2016 and April 9, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-004HR NDA.
If you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
